Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

12

Revenue 2017

Bayer

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bayer's 2013 sales performance.

Bayer

Aveo’s tivozanib is knocked back by FDA once again

Aveo’s tivozanib is knocked back by FDA once again the TIVO-1 trial of VEGF inhibitor tivozanib – then partnered with Astellas – which compared the drug to Bayer’s VEGF drug Nexavar (sorafenib) in renal cell carcinoma (RCC).

New faces at Healthware Group and HRW

New faces at Healthware Group and HRW Commenting on her new role, Milburn said “from CVS and Sleepio to OneDrop and Bayer, to Happify and Sanofi, every day more and more strategic partnerships are being born between various

Roche eyes filings for Tecentriq/Avastin combo in liver cancer

Roche eyes filings for Tecentriq/Avastin combo in liver cancer plus anti-VEGF antibody Avastin (bevacizumab) or Bayer’s Nexavar (sorafenib), a standard first-line therapy for HCC.

Finalists

by AbbVie. with support from Lucid Group. Marketing Capability Development. by Bayer Russia.

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD Novartis’ drug was the first VEGF inhibitor to reach the market for wet AMD but is facing the triple challenge of Bayer/Regeneron’s rival drug  Eylea (aflibercept) – now the market ... and Bayer adding another $2.1bn from other markets.

[ Previous 5 results ] 7 8 9 10 11 12 13 14 15 16 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....

Infographics